BU-NOT-SET

CONTACT US
Identifying impurities using advanced analytics
  • Analytical chemistry
Eyes
Insight
Recipharm on the impact of COVID-19 on API supply
  • Industry trends
Eyes
Insight
The role of excipient selection in the development of orally disintegrating tablets
  • Drug product
Eyes
Insight
Solving analytical method challenges to advance animal antibiotic
  • Analytical chemistry
Hand vial stand
Case study
The outlook for a year of change
  • Industry trends
Eyes
Insight
Can oral solid dose keep its place as the leading dosage form?
  • Drug product
Eyes
Insight
Relocating API supply to avoid over-reliance
  • Drug substance
Eyes
Insight
Modified release fixed dose combination product with two poorly soluble drug substances
  • Drug product
pellets
Case study
Patient centricity during drug development and commercialisation
  • Drug product
Eyes
Insight
Poster
  • Drug substance
Recipharm and Oncopeptides: Successful collaboration in the development of melflufen, a peptidase-potentiated alkylating agent in clinical trials
Fact sheet
  • Analytical chemistry
Recipharm Analytical Solutions™
Fact sheet
  • Analytical chemistry
Impurity identification
Fact sheet
  • Analytical chemistry
Stability studies
Fact sheet
  • Analytical chemistry
Extractables & leachables testing
Insight
  • Industry trends
Pharmaceutical mergers and acquisitions: opportunities and drivers for CDMOs
Insight
  • Industry trends
Global expansion in the CDMO field
Fact sheet
  • Drug product
Fixed dose combinations - for improved patient compliance
Insight
  • Industry trends
The current state of contract manufacturing